Clinical Trial Update: Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms [Phase 1]

View source ↗

Summary

This clinical trial update notes a Phase 1 study of Onvansertib for recurrent or refractory chronic myelomonocytic leukemia and myelodysplastic/myeloproliferati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Chronic Myeloid Leukemia
• Myelodysplastic Myeloproliferative Neoplasm
• Myelodysplastic Myeloproliferative Neoplasm Not Otherwise Specified
• Myelomonocytic Leukemia

Drugs mentioned

• Onvansertib (onvansertib)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia | Phase 1 | Status: RECRUITING